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Abstract
Background. Inflammation is involved in all stages of development of atherosclerotic plaques. Currently, percuta-
neous coronary intervention (PCI) is a widely used method of treatment of coronary artery disease (CAD) when 
combined with optimal medical therapy (OMT). However, there is still controversy over invasive versus optimal 
pharmacological treatment in stable CAD (SCAD). Systemic inflammatory response triggered by PCI may limit its 
effectiveness in patients with SCAD.
Objectives. We aimed to evaluate plasma CRP and its relation to thrombin generation and platelet reactivity both 
early after the procedure and in a  one-month observation following successful PCI with stent implantation, in 
patients with SCAD and OMT, including statins.
Material and Methods. We conducted a prospective study, in which CRP, platelet activation, thrombin generation 
and time course of prothrombin activation were determined at baseline, 3–5 days and 30 days after successful PCI 
with stent implantation, in 50 consecutive patients with SCAD, on chronic statin therapy.
Results. Early after PCI CRP increased by 176% as compared with baseline (p < 0.001) and one-month after angio-
plasty CRP was still 54% higher than before the procedure (p = 0.002). In multivariate model prolonged increase in 
CRP 1 month after PCI was independently associated with P2Y12-reactivity index (PRI) (p = 0.04) and maximum 
concentration of thrombin (p = 0.003), both measured 30 days after the procedure.
Conclusions. Post-procedural CRP increase, which persists at least one month in patients with SCAD, after elective 
PCI with stent implantation, is one of the main finding of our study. We demonstrated the relationship between 
prolonged post-PCI inflammatory reaction, reflected by elevated CRP, and increased thrombin generation and low 
platelets’ response to clopidogrel, which may account for limited benefits of PCI in stable coronary patients. It may 
be advisable to assay post-procedural CRP in each patient with SCAD, who underwent PCI to predict those, with 
potentially low response to clopidogrel (Adv Clin Exp Med 2015, 24, 6, 979–985).
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thrombin generation.
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The role of inflammation in the pathogenesis 
of atherosclerosis has been demonstrated in both 
experimental models and clinical trials  [1, 2]. In-
flammation is involved in all stages of development 
of atherosclerotic plaques-formation, vulnerabili-
ty and rupture  [3]. Local endothelial dysfunction 
promotes low-density lipoproteins (LDL) accumu-
lation, which are then oxidized. Oxidized LDL then 
triggers an inflammatory reaction, which signals 
immune cells, such as monocytes/macrophages, 
neutrophils, distinct classes of T  lymphocytes, 
dendritic cells, and potentially mast cells  [1,  2]. 
One of the most widely used markers of system-
ic inflammation is C-reactive protein (CRP). It is 
an acute phase reactant which is produced main-
ly by hepatocytes in response to interleukin-6 and, 
to a  much lesser extent, locally by coronary ar-
tery smooth muscle cells  [4]. CRP has been indi-
cated to be an independent predictor of myocardi-
al infarction (MI), stroke and cardiovascular death 
both in primary prevention as well as in patients 
with coronary artery disease (CAD) [5–8]. The im-
pact of CRP on long-term prognosis, in-stent re-
stenosis and major adverse cardiovascular events 
(MACE) after successful percutaneous coronary 
intervention (PCI), has been shown in clinical tri-
als  [9, 10]. Moreover, coronary atheroma regres-
sion and MACE reduction have also been shown 
to correlate with statin-mediated CRP lowering in 
patients treated with maximally intensive statin 
therapy [11]. CRP has been suggested not only to 
be the marker of inflammation, but also to exert 
complex modulatory effects that participate in in-
flammatory processes associated with atheroma-
tous plaque vulnerability and progression of coro-
nary stenosis [12].
Endothelium plays also a major role in the re-
ciprocal relationship between inflammation and 
coagulation  [13]. CRP-mediated cell surface in-
creased expression of TF, upon procoagulant ac-
tivity, induces a proinflammatory response medi-
ated by TF-FVIIa complexes directly, or through 
protease-activated receptors (PAR)  [14]. Throm-
bin, whose generation is stimulated by TF, besides 
its clotting properties, also activates PAR recep-
tors, which is a possible effector mechanism linked 
with atherosclerosis  [14]. Another link between 
coagulation and inflammation are platelets-bind-
ing of P-selectin on activated platelets with its li-
gand, present on majority of leukocytes, promotes 
the inflammatory response [13].
PCI is currently a widely used method of treat-
ment of CAD when combined with optimal med-
ical therapy (OMT)  [15]. However, there is still 
controversy over invasive vs. optimal pharmaco-
logical treatment in stable CAD (SCAD) as sev-
eral studies have failed to demontrate that PCI 
reduces the risk of MACE over OMT in patients 
with SCAD [16–18]. During PCI, balloon inflation 
causes both plaque rupture and endothelial injury 
with exposure of deeper layers of artery wall. These 
insults are strong pro-inflammatory and procoag-
ulant stimuli. Moreover, intervention is limited to 
the single plaque, whereas there may be numerous 
vulnerable plaques prone to destabilization by the 
inflammatory processes.
In previous studies PCI in patients with 
SCAD has been shown to cause CRP eleva-
tion  [19]. We hypothesized that systemic in-
flammatory response triggered by PCI may lim-
it its effectiveness in patients with SCAD. The 
aim of the present study was to evaluate plasma 
CRP and its relation to thrombin generation and 
platelet reactivity both early after the procedure 
and in a  one-month observation following suc-
cessful PCI with stent implantation in patients 
with stable angina and optimal medical treat-
ment, including statins.
Material and Methods
The study group included 50 consecu-
tive patients (38  male and 12  female; mean age 
63 ± 9.5 years) with SCAD, on chronic statin ther-
apy at least one month prior to the study enrol-
ment, who underwent successful PCI with stent 
implantation. The authors conducted a  prospec-
tive study, in which CRP was measured at base-
line, 3–5  days and 30  days after PCI with stent 
implantation. The authors also assayed platelet 
activation markers (platelet aggregation, P2Y12- 
-reactivity index/PRI/and P-selectin expression 
on platelets), thrombin generation, time course 
of prothrombin activation and oxidized low-den-
sity lipoprotein. Several atherosclerosis risk fac-
tors were assessed by medical history or laborato-
ry analyses including: blood pressure, lipidogram, 
renal function, diabetes, obesity and smoking, 
previous CAD, stroke or PAD as well as family 
history of CAD.
Hypertension was defined as either the mean 
from at least two blood pressure measurements 
consistently not lower than 140  mm Hg systolic 
or 90  mm Hg diastolic over at least two separate 
days or patients currently receiving antihyperten-
sive therapy.
In the study population, a  lipid-lowering 
therapy or cholesterol LDL level of 1.8  mmol/L 
(70 mg/dL) and higher was considered diagnostic 
for hypercholesterolemia. Renal function impair-
ment was assessed on the basis of a decreased glo-
merular filtration rate (eGFR) < 60 mL/min/1.73 m2 
by the MDRD formula [20].
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Diagnosis of diabetes was adopted from 2013 
ESC guidelines. In brief, fasting glycemia equal 
to or exceeding 7.0  mmol/L (126  mg/dL) during 
2 measurements or 11.0  mmol/L (200  mg/dL) in 
one random blood sample or patients currently re-
ceiving hypoglycemic medication was considered 
diagnostic.
Obesity was regarded present if the patient’s 
body mass index (BMI) was ≥ 30 kg/m2. Definition 
of metabolic syndrome was adopted from the 2009 
IDF statement [21].
Patients were interviewed with regard to cur-
rent or former smoking habit, CAD, stroke or 
PAD history and family history of CAD.
Exclusion criteria were as follows: acute coro-
nary syndrome, history of inflammatory, autoim-
mune, neoplastic or infectious diseases, history of 
bleeding, oral anticoagulant therapy, platelet count 
<  100,000/µL, serum creatinine  >  177  µmol/L 
(2  mg/dL), liver injury (alanine transaminase 
>  1.5  times above the upper limit of the refer-
ence range) or severe obesity (body mass index 
[BMI] > 35 kg/m²).
The study was compliant with the Good Clin-
ical Practice International Conference on Har-
monization rules and was approved by the Ethics 
Committee of Jagiellonian University. Written in-
formed consent was obtained from each patient.
Laboratory Investigations
Fasting blood samples were obtained between 
8.00 and 10.00 am, after at least 10 h  of fasting, 
from an antecubital vein with minimal stasis. 
Routine blood tests (complete blood count, glu-
cose, lipid profile, serum creatinine) were assayed 
by automated laboratory techniques. Blood sam-
ples were centrifuged within 30 min of collection 
and the supernatant was stored at –80°C. High- 
-sensitivity C-reactive protein was measured by 
latex nephelometry. Platelet reactivity was mea-
sured by light transmittance aggregometry upon 
stimulation with 5 and 20  mmol/L of ADP and 
0.5  mmol/L of arachidonic acid; PRI was calcu-
lated according to standard protocols and a stan-
dardized assay with quantitative flow cytometry; 
P-selectin expression on the platelets was deter-
mined by flow cytometry. The CAT was used to 
analyze thrombogram. For the analysis we used 
the maximum concentration of thrombin gen-
erated (Cmax). Prothrombin fragment 1.2(F1.2) 
was determined by immunoenzymatic assays. 
The time course of prothrombin activation was 
analyzed and quantified by quantitative Western 
blotting. All laboratory investigations were per-
formed by the investigator blinded to the sample 
origin.
Statistical Analysis
STATISTICA 8.0 software package (Statsoft 
Inc.) was used for statistical analyses. Continuous 
variables were expressed as mean ± SD or median 
(IQR) and categorical variables as numbers (per-
centage). First, the Shapiro-Wilk statistic was used 
to check continuous variables for normal distribu-
tion. When the variables were not normally dis-
tributed, non-parametric test were used. CRP lev-
els of three time points were compared with the 
use of the Friedman test. The Wilcoxon test was 
used to examine the differences between base-
line and 3–5 days as well as between baseline and 
1 month CRP level. To test the association between 
two variables, the Pearson rank correlation coef-
ficient was calculated. Forward stepwise logistic 
regression analysis was performed including de-
mographic and clinical parameters. A probability 
value < 0.05 was considered statistically significant.
Results
We analyzed 50 consecutive patients (38 male 
and 12  female; mean age 63  ±  9.5  years) with 
SCAD on chronic statin therapy who were under-
going PCI. Baseline demographics, clinical charac-
teristics, procedural characteristics, and laboratory 
results of study population are shown in Table 1.
CRP in 3 time points were found to be statis-
tically significant (p  <  0.01). Its baseline concen-
tration was 2.21 (0.1–8.22) mg/L. Early after PCI, 
CRP increased by 176% as compared with baseline 
(6.12 (0.1–28.77) mg/L; p < 0.001). One-month af-
ter PCI, CRP level did not return to baseline values 
(3.41 (0.1–22.32) mg/L) and was still 54% higher 
than before the procedure (p = 0.002) (Fig. 1).
Fig. 1. CRP in 3 time points
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Univariate linear regression showed that both 
CRP 3–5 days after PCI, as well as early post-pro-
cedural CRP increases were associated with fac-
tor XIII measured 3–5  days after PCI (p  =  0.012 
and p = 0.026, respectively). Early post-procedural 
CRP level was associated with expression of P-se-
lectin on the platelets at the same time (0 = 0.017). 
We have also observed the association between the 
rate of prothrombin activation and platelets reac-
tivity upon stimulation with 20  mmol/L of ADP 
3–5  days after PCI (p  =  0.025) and between the 
rate of prothrombin activation and PRI one month 
after the procedure (p = 0.016). In the univariate 
model CRP in a 1 month follow-up was associated 
with stent size (p = 0.032).
In multivariate model (Forward Stepwise Re-
gression) prolonged increase in CRP 1 month af-
ter PCI was independently associated with PRI 
(p = 0.04) and maximum concentration of throm-
bin (p  =  0.003), both measured 30  days after the 
procedure (Table 2).
Discussion
We have shown that PCI with stent implan-
tation causes an early increase in hs-CRP in sta-
ble coronary patients on optimal pharmacological 
treatment, including chronic statin therapy, an-
tiplatelet drugs and beta-blockers. To the best of 
our knowledge, our study is the first to demon-
strate prolonged inflammatory reaction to at least 
1 month after PCI. Moreover, we have found that 
prolonged post-angioplasty CRP increase is asso-
ciated with higher thrombin generation and low-
er platelets’ response to clopidogrel, which are also 
novel findings.
Our observation of early CRP increase af-
ter PCI is in accordance with other clinical trials 
[19, 22]. Our study followed post-procedural CRP 
in the long-term, which only few other studies as-
sessed [23]. We have observed the relationship be-
tween post-angioplasty CRP increase in 1 month 
follow-up and higher PRI measured 30  days af-
ter PCI. This suggests that post-procedural sys-
temic inflammatory reaction diminished plate-
lets’ response to clopidogrel. This mechanism may 
potentially limit PCI benefits in stable coronary 
patients. In previous studies, higher CRP has been 
shown to predict the risk of in-stent thrombosis 
after treatment with DES [24], which might be re-
lated to the lower platelets’ response to clopido-
grel observed in our study. Moreover, Bernloch-
ner et  al. have demonstrated that elevated CRP 
and white blood count were associated with high 
platelet reactivity in patients under chronic clop-
idogrel treatment  [25]. Of note, high on-treat-
ment platelet reactivity is an important predictor 
of poor clinical outcomes in patients undergoing 
coronary stenting [26]. Nevertheless, high platelet 
reactivity on dual antiplatelet therapy with aspirin 
and clopidogrel is quite frequent, especially in pa-
tients with cytochrome P450  2C19 loss-of-func-
tion polymorphism [15].
We have also found that prolonged post- 
-procedural CRP increase was associated with 
thrombin generation, which may reflect inflam-
mation-dependent coagulation response to en-
dothelium injury  [27] and may also account for 
Table 1. Baseline characteristic of study population
Age (years ± SD) 63.1 ± 9.5
Female gender; n(%) 12 (24)
History of CAD; years (min–max) 7.5 (1–30)
Fasting glucose; mmol/L (min–max) 5.4 (4.1–13.1)
BMI kg/m2 (min–max) 29 (21–39)
MVD; n (%) 38 (77.6)
Previous MI; n (%) 20 (40)
Previous CABG; n (%) 5 (10)
Previous stroke; n (%) 14 (28)
Previous PCI; n (%) 9 (18)
Hypertension; n (%) 48 (96)
DM; n (%) 16 (32)
Insulin; n (%) 5 (10)
Hyperlipidemia; n (%) 50 (100)
Smokers; n (%) 24 (48)
Current smoking; n (%) 10 (20)
Family history of CAD; n (%) 30 (60)
CKD (GFR < 60); n (%) 10 (20)
Metabolic syndrome; n (%) 36 (72)
Beta-blocker; n (%) 43 (86)
ACE-I; n (%) 44 (88)
AT1; n (%) 7 (14)
Statins; n (%) 50 (100)
Nitrates; n (%) 20 (40)
Ca-blockers; n (%) 26 (52)
CAD – coronary artery disease; BMI – body mass index; 
MVD – multivessel disease; MI – myocardial infarction; 
CABG – coronary artery by-pass grafting; PCI – percu-
taneous coronary intervention; DM – diabetes mellitus; 
CKD – chronic kidney disease; ACE-I – angiotensin con-
verting enzyme inhibitors; AT1 – angiotensin 1 receptor 
antagonists; Ca-blockers – calcium channel antagonists.
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limited PCI benefits in stable angina. In SCAD, 
the atherosclerotic plaque is covered with a  non-
thrombogenic endothelialized fibrous cap. Dis-
ruption of this cap during PCI enables circulating 
blood to contact procoagulant elements within the 
plaque  [29] with subsequent coagulation and ac-
tivation of platelets. Increased thrombin genera-
tion after balloon-mediated plaque injury has been 
shown in both patients with ineffective anticoagu-
lation [28] and those adequately heparinized [29]. 
Association between high CRP and thrombin gen-
eration in CAD has previously been reported in 
patients with advanced SCAD [30], unstable angi-
na [31] and 5 years after acute myocardial infarc-
tion, especially in those with new coronary isch-
emic events  [32]. However, we have not found 
other studies to demonstrate the correlation be-
tween prolonged post-angioplasty CRP increase 
and higher thrombin generation in patients with 
SCAD.
The extent of thrombin generation has been 
shown to be related with the extent of vascular in-
jury  [29]. In patients with higher thrombin gen-
eration after PCI, increased platelet activation 
has been observed  [28]. This may be due to high 
thrombin concentrations- a  potent platelet acti-
vator, or balloon-mediated plaque injury. In our 
study we did not observe a  correlation between 
thrombin generation and platelet activation. How-
ever, we found an association between the rate of 
prothrombin activation and platelets reactivity 
3–5  days after PCI and between the rate of pro-
thrombin activation and PRI one month after the 
procedure. In our study patients received dual an-
tiplatelet therapy with aspirin and clopidogrel, thus 
one may expect stronger platelet inhibition. More-
over, they were on chronic statin therapy, known 
to affect thrombin generation, platelet activity and 
CRP  [33]. Nevertheless, it is possible that lower 
platelets’ response to clopidogrel observed in our 
study was related to higher thrombin generation.
Increased thrombin generation may have great 
clinical implications in the long term. Besides acti-
vating platelets, thrombin acts as a growth factor on 
vascular smooth muscle. Therefore, thrombin par-
ticipates in intimal hyperplasia, and potentially re-
stenosis, due to increased smooth muscle prolifera-
tion [29]. The impact of thrombin on both the early 
stages of plaque formation and in the advanced 
stages of atherosclerotic plaque progression, and 
subsequent destabilization, has been shown [27].
We hypothesize that a  systemic inflamma-
tory reaction triggered by coronary angioplasty 
may destabilize non-target plaques and as a  con-
sequence, cause the progression of atherosclerosis. 
This may be another factor that limits the bene-
fits of PCI in stable coronary patients. It has pre-
viously been shown that increased CRP predicted 
progression of non-target lesions in patients, who 
underwent PCI with stent implantation for culprit 
lesions in SCAD [10]. Rapid progression of steno-
sis is a strong predictor of cardiovascular risk, re-
gardless of being clinically silent or associated with 
acute coronary events [34].
Our study has several limitations. First, the 
study population was limited. Also we did not as-
sess clinical end-points in long-term observation, 
thus we were not able to assess the effect of per-
sistent post-PCI inflammatory reaction on clinical 
outcome. Control angiography for determining 
potential progression of atherosclerotic lesions in 
long-term follow-up was not performed, thus we 
did not assess the impact of long-term post-proce-
dural CRP increase on clinically silent atheroscle-
rotic plaque progression.
In conclusion, a  post-procedural CRP in-
crease, which persists at least one month in pa-
tients with stable CAD, who underwent elective 
coronary angioplasty with stent implantation, 
is one of the main findings of our study. More-
over, we have demonstrated the relationship be-
tween prolonged post-PCI inflammatory reaction, 
Table 2. Multiple Regression Model with CRP increase 1 month after PCI as the dependent variable
b* Std. err. of b* b Std. err. of b p
Thrombin_2 0.717 0.209 0.072 0.020 0.003
PRI_2 0.466 0.210 0.126 0.056 0.039
Age 0.296 0.192 0.171 0.110 0.141
Creatinine –0.278 0.187 –0.071 0.048 0.156
FXIII%_2 –0.190 0.180 –0.060 0.057 0.304
PCI – percutaneous coronary intervention; b* – standardized regression coefficients; Std. err. of b* – standardized error of 
b*; b – raw regression coefficients; Std. err. of b – standardized error of b; thrombin_2 – maximum concentration of throm-
bin generated 1 month after percutaneous coronary intervention (PCI); PRI_2 – P2Y12 reactivity index 1 month after PCI; 
FXIII%_2 – factor XIII 1 month after PCI.
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reflected by elevated CRP and increased throm-
bin generation and low platelets’ response to clop-
idogrel, which may account for limited benefits of 
PCI in stable coronary patients. According to our 
findings, it may be advisable to assay post-proce-
dural CRP in each patient with SCAD, who under-
went coronary angioplasty to predict those, with 
potentially low-response to clopidogrel.
References
 [1] Libby P, Ridker PM, Hansson GK: Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll 
Cardiol 2009, 54, 2129–2138.
 [2] Jawień J: New insights into immunological aspects of atherosclerosis. Pol Arch Med Wewn 2008, 118, 127–131.
 [3] Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, 
Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F: Centers for Disease Control and 
Prevention; American Heart Association. Markers of inflammation and cardiovascular disease. AHA//CDC 
Scientific Statement. Circulation 2003, 107, 499.
 [4] Calabró P, Willerson JT, Yeh ET: Inflammatory cytokines stimulated C-reactive protein production by human 
coronary artery smooth muscle cells. Circulation 2003, 108, 1930–1932.
 [5] Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M: C-reactive protein, fibrino-
gen, and cardiovascular disease prediction. N Engl J Med 2012, 367, 1310–1320.
 [6] Ridker PM, Kastelein JJ, Genest J, Koenig W: C-reactive protein and cholesterol are equally strong predictors of 
cardiovascular risk and both are important for quality clinical care. Eur Heart J 2013, 34, 1258–1261.
 [7] Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, 
MacFadyen JG, Nordestgaard BG, Shepherd J,Willerson JT, Glynn RJ: JUPITER Study Group. Rosuvastatin to 
prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359, 2195–2207.
 [8] Kralisz P, Kemona H, Dobrzycki S, Bachórzewska-Gajewska H, Nowak K, Sawicki Z: Changes in C-reactive 
protein levels following coronary stent implantation depend on the extent of periprocedural arterial injury. Kardiol 
Pol 2006, 64, 364–371.
 [9] Li JJ, Ren Y, Chen KJ, Yeung AC, Xu B, Ruan XM, Yang YJ, Chen JL, Gao RL: Impact of C-reactive protein on 
in-stent restenosis: a meta-analysis. Tex Heart Inst J 2010, 37, 49–57.
[10] Xu YL, Li JJ, Xu B, Zhu CG, Yang YJ, Chen JL, Qiao SB, Yuan JQ, Qin XW, Ma WH, Yao M, Liu HB, Wu YJ, 
Chen J, You SJ, Dai J, Xia R, Gao RL: Increased plasma C-reactive protein level predicts rapid progression of non-
target atherosclerotic lesions inpatients with stable angina after stenting. Chin Med J (Engl) 2011, 124, 3022–3029.
[11] Puri R, Nissen SE, Libby P, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, 
Kataoka Y, Nicholls SJ: C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coro-
nary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation 2013, 
128, 2395–2403.
[12] Nakachi T, Kosuge M, Hibi K, Ebina T, Hashiba K, Mitsuhashi T, Endo M, Umemura S, Kimura K: C-reactive 
protein elevation and rapid angiographic progression of nonculprit lesion in patients with non-ST-segment eleva-
tion acute coronary syndrome. Circ J 2008, 72, 1953–1959.
[13] O’Brien M: The reciprocal relationship between inflammation and coagulation. Top Companion Anim Med 2012, 
27, 46–52.
[14] Ten Cate H: Tissue factor-driven thrombin generation and inflammation in atherosclerosis. Thromb Res 2012, 
129, 38–40.
[15] Gajos G, Zalewski J, Nessler J, Zmudka K, Undas A, Piwowarska W: Polyunsaturated omega-3 fatty acids improve 
responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 
loss-of-function polymorphism. Kardiol Pol 2012, 70, 439–445.
[16] Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, Bangalore S: Percutaneous coronary inter-
vention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of 
randomized clinical trials. Circ Cardiovasc Interv 2012, 5, 476–490.
[17] Thomas S, Gokhale R, Boden WE, Devereaux PJ: A meta-analysis of randomized controlled trials comparing per-
cutaneous coronary intervention with medical therapy in stable angina pectoris. Can J Cardiol 2013, 29, 472–482.
[18] Gorenoi V, Hagen A: Percutaneous coronary intervention in addition to optimal medical therapy for stabile coro-
nary artery disease – a systematic review and meta-analysis. Dtsch Med Wochenschr 2014, 139, 1039–1045.
[19] Almagor M, Keren A, Banai S: Increased C-reactive protein level after coronary stent implantation in patients 
with stable coronary artery disease. Am Heart J 2003, 145, 248–253.
[20] Klahr S: The modification of diet in renal disease study. N Engl J Med 1989, 320, 864–866.
[21] Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, 
Smith SC Jr: International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, 
Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis 
Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: A Joint Interim 
Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, 
Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis 
Society; and International Association for the Study of Obesity. Circulation 2009, 120, 1640–1645.
[22] Sánchez-Margalet V, Cubero JM, Martín-Romero C, Cubero J, Cruz-Fernández JM, Goberna R: Inflammatory 
response to coronary stent implantation in patients with unstable angina. Clin Chem Lab Med 2002, 40, 769–774.
Prolonged Post-PCI CRP Increase in SCAD 985
[23] Goldberg A, Zinder O, Zdorovyak A, Diamond E, Lischinsky S, Gruberg L, Markiewicz W, Beyar R, Aronson D: 
Diagnostic coronary angiography induces a systemic inflammatory response in patients with stable angina. Am 
Heart J 2003, 146, 819–823.
[24] Montone RA, Sabato V, Sgueglia GA, Niccoli G. Inflammatory mechanisms of adverse reactions to drug-eluting 
stents. Curr Vasc Pharmacol 2013, 11, 392–398.
[25] Bernlochner I, Steinhubl S, Braun S, Morath T, Jaitner J, Stegherr J, Mehilli J, von Beckerath N, Schömig A, 
Kastrati A, Sibbing D: Association between inflammatory biomarkers and platelet aggregation in patients under 
chronic clopidogrel treatment. Thromb Haemost 2010, 104, 1193–200.
[26] Woo JS, Kim W, Jang HH, Kim JB, Kim WS, Kim KS. Effect of platelet reactivity, endothelial function, and 
inflammatory status on outcomes in patients with stable angina pectoris on clopidogrel therapy. Am J  Cardiol 
2014, 113, 786–792.
[27] Kleinegris MC, Ten Cate-Hoek AJ, Ten Cate H. Coagulation and the vessel wall in thrombosis and atherosclero-
sis. Pol Arch Med Wewn 2012, 122, 557–566.
[28] Borries M, Heins M, Fischer Y, Stiegler H, Peters A, Reinauer H, Schoebel FC, Strauer BE, Leschke M: Changes 
of hemostasis, endogenous fibrinolysis, platelet activation and endothelins after percutaneous transluminal coro-
nary angioplasty in patients with stable angina. J Am Coll Cardiol 1999, 34, 486–493.
[29] Marmur JD, Merlini PA, Sharma SK, Khaghan N, Torre SR, Israel DH, Ardissino D, Ambrose JA: Thrombin 
generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol 
1994, 24, 1484–1491.
[30] Stepień E, Plicner D, Branicka A, Stankiewicz E, Pazdan A, Sniezek-Maciejewska M, Górkiewicz I, Kapelak B, 
Sadowski J: Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and 
using calibrated automated thrombogram in patients with advanced coronary artery disease. Pol Arch Med Wewn 
2007, 117, 297–305.
[31] Niccoli G, Biasucci LM, Biscione C, Buffon A, Siviglia M, Conte M, Porto I, Graziani F, Liuzzo G, Crea F: 
Instability mechanisms in unstable angina according to baseline serum levels of C-reactive protein: the role of 
thrombosis, fibrinolysis and atherosclerotic burden. Int J Cardiol 2007, 30, 122, 245–247.
[32] Vanschoonbeek K1, Feijge MA, Paquay M, Rosing J, Saris W, Kluft C, Giesen PL, de Maat MP, Heemskerk JW: 
Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin genera-
tion. Arterioscler Thromb Vasc Biol 2004, 24, 1734–1740.
[33] Undas A, Celińska-Löwenhoff M, Kaczor M, Musial J: New nonlipid effects of statins and their clinical relevance 
in cardiovascular disease. Thromb Haemost 2004, 91, 1065–1077.




Department of Coronary Disease and Heart Failure





Conflict of interest: None declared
Received: 5.03.2015
Revised: 21.05.2015
Accepted: 3.08.2015
